MEDP - NASDAQ
Medpace Holdings, Inc.
$450.81
+1.2%Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
At a Glance
Live SnapshotMedpace Holdings, Inc. Management Team
Ms. Lauren Morris
Associate Director of Investors Relations
Dr. August James Troendle M.D.
Chairman & Chief Executive Officer
Compensation
$1,530,114
Mr. Stephen P. Ewald J.D.
Chief Compliance Officer, General Counsel & Corporate Secretary
Compensation
$871,950
Mr. Kevin M. Brady
Chief Financial Officer & Treasurer
Compensation
$656,750
Mr. Brandon Ebken
Chief Information Officer
Ms. Susan E. Burwig BSN, MA
Executive Vice President of Operations
Compensation
$1,064,069
Mr. Jesse J. Geiger BBA, CPA
President
Compensation
$939,067
Mr. Weimin Gai MS
Senior Vice President of Biometrics
Mr. John T. Wynne MBA
Senior Vice President of Commercial Operations & Clinical Pharmacology Unit
Mr. Todd Meyers
Vice President of Business Development & Marketing
Medpace Holdings, Inc. Insider Positioning
During the last 12 months, insiders have sold $333.22M worth of MEDP shares, with no buying activity reported.
3 Months
0
0.00
48.1K
21.79M
-21.8M
-$21.79M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
393.6K
236.75M
-236.8M
-$236.75M
9-12 Months
0
0.00
162.5K
74.68M
-74.7M
-$74.68M
Top Buyers
No buying activity
Top Sellers
Troendle August J.
Director, 10 Percent Owner, Officer: Ceo
$207.59M
Geiger Jesse J
Officer: President
$60.05M
Burwig Susan E
Officer: Exec. Vp, Operations
$32.46M
Ewald Stephen P
Officer: General Counsel & Corp. Secy.
$17.83M
Brady Kevin M.
Officer: Cfo & Treasurer
$7.22M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $333.22M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MEDP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 15, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 03, 2024 | May 17, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 05, 2023 | April 05, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 06, 2022 | May 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 30, 2021 | May 14, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 01, 2020 | May 15, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 03, 2019 | May 17, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 05, 2018 | May 18, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 05, 2017 | May 19, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.